第一至尊娱乐平台网主办
»您现在的位置: 第一至尊娱乐平台网 >> 至尊娱乐平台焦点 >> 文传商讯 >> 正文

Results from RE-SPECT CVT published - first trial of NOAC in cerebral venous thrombosis

2019/9/4 16:41:26  文章来源:文传商讯  作者:文传商讯
文章简介: StudypublishedinJAMANeurologyinvestigatedPradaxa(dabigatranetexilate)inpatientswithcerebralvenousandduralsinusthrombosis(CVT) Firstexplo

Study published in JAMA Neurology investigated Pradaxa (dabigatran etexilate) in patients with cerebral venous and dural sinus thrombosis (CVT)
First exploratory study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this population
The study is part of Boehringer Ingelheim’s commitment to advancing thrombosis care

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of primary analysis from RE-SPECT CVT®, the first exploratory, prospective, randomised controlled study of a NOAC in patients with blood clots in the veins or venous sinuses of the brain. The trial investigated the safety and efficacy of Pradaxa® (dabigatran etexilate) and dose-adjusted warfarin in patients with CVT.

The results provide insight into the role of anticoagulation in patients with CVT of mild-moderate severity. In the study, there were no recurrent venous thromboembolism (VTE) events in either treatment group. The trial also found that the rate of bleeding was low, with two patients in the warfarin arm (3.3%) and one (1.7%) in the dabigatran arm developing a major bleed. There was no mortality in either treatment arm in this study.1

“Cerebral venous thrombosis, CVT, which affects predominantly young patients and women, can cause death and disability. Patients who survive the acute phase of CVT may suffer recurrent venous thrombosis. To prevent that, the usual clinical practice is to prescribe vitamin K antagonists (VKAs, such as warfarin). VKAs present limitations in terms of safety, dosing, reversibility and patient preference,” said Professor José M. Ferro, Director of the Department of Neurosciences and Mental Health at the Hospital Santa Maria in Lisbon, Portugal, and Chair of the RE-SPECT CVT Steering Committee. “RE-SPECT CVT was the largest trial performed in patients with CVT to date, enrolling 120 patients. The trial showed that the risk of recurrent VTE in CVT patients of mild to moderate severity under anticoagulant therapy with dabigatran for six months was low and associated with few major or clinically relevant bleeding events.”

The trial forms part of Boehringer Ingelheim’s ongoing commitment to expanding scientific knowledge of thrombosis care. Additionally, it furthers the understanding of the safety profile of dabigatran, which has been documented in the extensive RE-VOLUTION® trial and registry programme.2-24

About the RE-SPECT CVT® study 
Randomised evaluation of the safety and efficacy of dabigatran etexilate versus dose adjusted warfarin in patients with cerebral venous thrombosis (RE-SPECT CVT®)1 

RE-SPECT CVT® was a prospective, randomised exploratory study assessing the safety and efficacy of dabigatran etexilate and warfarin in patients who suffer from CVT. The open-label study involved 120 patients from nine countries and looked to evaluate the suitability of dabigatran etexilate and warfarin for the treatment and secondary prevention of blood clots in the veins or venous sinuses of the brain. Patients aged ≥ 18 years old with a confirmed diagnosis of CVT (with or without haemorrhagic stroke) were randomised to receive either warfarin or dabigatran etexilate.1

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/re-spect-cvt-study-data-published

Intended audiences: 
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

分享到:
第一至尊娱乐平台网免责声明:
1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
2、文章来源为均为其它现金娱乐网的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供亚博国际登录网址信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
3、本网站所载文章、数据、网友平博体育网址等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一至尊娱乐平台网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
发表评论

【发表评论】(网友评论内容只代表网友观点,与本站立场无关!)
 姓 名:
 评 分: 1分 2分 3分 4分 5分
 评论内容:
验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及bet007.c0m人民其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏平博体育网址稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  至尊娱乐男篮生死战是怎么回事?至尊娱乐男篮生死战具体
     瑞幸一年关147家外卖厨房怎么回事?小鹿茶不惜零
    [银行]  银行怎么了?六大银行上半年减员近3.5万人
     才半年时间!六大银行就减少3.5万人,还关了277
    [股票]  200亿"福布斯富豪"彻底凉了?公司美女总裁称病不
     暴风集团冯鑫事件 其多家企业为失信公司
    [基金]  2019年赚钱的公募基金都有谁 2019年赚钱基金排名
     大盘重回3000点 大涨底气在哪?基金最新解读来了
    [保险]  人保车险理赔时间规定
     职工医保和新农合医保哪个好?主要看这三点
    [期货]  油价调整蕞新消息:9月3日24时 本轮成品油上调板
     消息人士:至尊娱乐考虑大幅放开期货市场 以吸引海外
    [股评]  六大券商周四看好六大板块(9/5)
     券商评级:三大指数上涨 九股迎来掘金良机(9/5
    [港股]  小米120亿回购引争议:现金流承压 谁在抛售谁被
     No zuo no die!国泰航空19天蒸发超百亿,遭强烈
    [美股]  苹果2019年秋季发布会什么时候 相关产业链概念股
     百度广告困境:代理商无奈 广告主逃离
    [至尊娱乐平台登录]  突发!美元兑人民币逼近7.2!触及7.18345
     人民币对美元汇率中间价报7.0211元 下调75个基点
    [债券]  足球开户网超越至尊娱乐 成美债最大海外持有国
     中城集团旗下多支债券违约 14亿银行存款被冻结
    [黄金]  黄金疯涨!六年前血战华尔街的“至尊娱乐大妈”解套
     刘智辛:欧美货币持稳,黄金日线三连阳,原油多
    [理财]  建国70周年币什么时候发行 2019建国70周年纪念币
     至尊娱乐女主播刘欣就热点问题对话CNBC
    [信托]  跌破8% 集合信托收益或继续下跌
     信托违约增多 预期收益9%的产品还能买吗?
    [房产]  2019年下半年房价走势会如何?房价会跌吗?
     至尊娱乐房企海外融资大幅缩水 环比下跌近八成
    [汽车]  特斯拉App宕机是怎么回事?至尊娱乐特斯拉App宕机事
     途观L七座版将于成都车展上市,与汉兰达正面交锋
  • 此栏目下没有推荐文章
  • | 设为至尊娱乐 | 加入收藏 | 关于我们 | dafabet中文 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 afinance.cn All Rights Reserved 版权所有·第一至尊娱乐平台网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以第一至尊娱乐平台网名义做股票推荐的行为均属违法!

    广告商的言论与行为均与第一至尊娱乐平台网无关!股市有风险,投资需谨慎。

    合作邮箱:必威客户端 合作电话:亚博国际登录网址 点击这里给我发消息

    条评论
    Sitemap